Pre-clinical studies of plasmin: Superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator

Thrombosis Research

Volumn 122, Issue SUPPL. 3, 2008, Pages

  Marder, Victor J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; PLASMIN; TAL 05 00018; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYSIS; HEART INFARCTION; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS;

ANIMALS; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; HUMANS; PLASMIN; RISK ASSESSMENT; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 50849116738     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.06.019     Document Type: Article

References (12)

1. Ambrus J.L., Ambrus C.M., Sokal J.E., et al. Clinical pharmacology of various types of fibrinolytic enzyme preparations. Am J Cardiol 6 (1960) 462-475
2. Douglas A.S., and McNicol G.P. Thrombolytic therapy. Br Med Bull 20 (1964) 228-232
3. Christensen L.R., and MacLeod C.M. A proteolytic enzyme of serum: characterization, activation and reaction with inhibitors. J Gen Physiol 28 (1945) 559-583
4. Sherry S. Mechanisms of fibrinolysis. In: Williams W.J., Beutler E., Erslev A.J., and Rundles R.W. (Eds). Hematology (1977), McGraw-Hill, New York 1297 Section 7, Chapter 4
5. Marder V.J., and Sherry S. Thrombolytic therapy: current status (1). N Engl J Med 318 (1988) 1512-1520
6. Marder V.J., and Sherry S. Thrombolytic therapy: current status (2). N Engl J Med 318 (1988) 1585-1595
7. Marder V.J. The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. Ann Intern Med 90 (1979) 802-808
8. Marder V.J., Landskroner K., Novokhatny V., et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 86 (2001) 739-745
9. Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 43 (1980) 77-89
10. Stewart D., Kong M., and Novokhatny V. Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood 101 (2003) 3002-3007
11. Califf R.M., Fortin D.F., Tenaglia A.N., and Sane D.C. Clinical risks of thrombolytic therapy. Am J Cardiol 69 (1992) 12A-20A
12. Jahan R., Stewart D., Vinters H.V., et al. Middle cerebral artery occlusion in the rabbit using selective angiography: application for assessment of thrombolysis. Stroke 39 (2008) 1613-1615